Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel.

dc.contributor.authorYepes, Edward
dc.contributor.authorVarela-M, Rubén E.
dc.contributor.authorLópez-Abán, Julio
dc.contributor.authorRojas-Caraballo, Jose
dc.contributor.authorMuro, Antonio
dc.contributor.authorMollinedo, Faustino
dc.date.accessioned2019-08-08T05:58:29Z
dc.date.available2019-08-08T05:58:29Z
dc.date.issued2015
dc.description.abstractSchistosomiasis is the third most devastating tropical disease worldwide caused by blood flukes of the genus Schistosoma. This parasitic disease is due to immunologic reactions to Schistosoma eggs trapped in tissues. Egg-released antigens stimulate tissue-destructive inflammatory and granulomatous reactions, involving different immune cell populations, including T cells and granulocytes. Granulomas lead to collagen fibers deposition and fibrosis, resulting in organ damage. Praziquantel (PZQ) is the drug of choice for treating all species of schistosomes. However, PZQ kills only adult Schistosoma worms, not immature stages. The inability of PZQ to abort early infection or prevent re-infection, and the lack of prophylactic effect prompt the need for novel drugs and strategies for the prevention of schistosomiasis.en_US
dc.identifier.issn1935-2727
dc.identifier.urihttps://repositorio.usc.edu.co:8443/xmlui/handle/123456789/519
dc.language.isoenen_US
dc.publisherPLoS Neglected Tropical Diseasesen_US
dc.titleInhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel.en_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel..pdf
Size:
3.99 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: